Metoprolol tartrate(CAS:56392-17-7)

Metoprolol Tartrate (CAS 56392-17-7) is one of the most mature and widely used highly selective beta-1 adrenergic receptor blocker APIs in the global cardiovascular pharmaceutical industry. With precise cardiac targeting, stable pharmacological efficacy and excellent long-term safety, it has become a cornerstone raw material for the prevention and treatment of hypertension, coronary heart disease, heart failure and arrhythmia. Included in major international pharmacopoeias, it is extensively applied in pharmaceutical production and new drug research. Featuring stable physical and chemical properties, high purity and low impurity content, Metoprolol Tartrate supports the production of common tablets and sustained-release dosage forms, meeting diverse clinical demands including emergency treatment and long-term chronic disease management.

In terms of pharmacological mechanism, Metoprolol Tartrate exhibits high cardiac selectivity. It specifically blocks beta-1 adrenergic receptors in the heart and kidneys, with negligible influence on beta-2 receptors in bronchial and vascular smooth muscle, effectively avoiding side effects such as bronchospasm and peripheral circulation disorders caused by non-selective beta blockers. Excessive sympathetic activation is a key cause of tachycardia, hypertension, myocardial ischemia and ventricular remodeling. By inhibiting abnormal sympathetic excitation, Metoprolol Tartrate significantly reduces heart rate, weakens myocardial contraction and lowers myocardial oxygen consumption, relieving myocardial ischemia. It also reduces cardiac output, inhibits renin release and blocks RAAS activation to stabilize blood pressure. Furthermore, it prolongs the effective refractory period of cardiomyocytes, suppresses reentrant rhythms and achieves reliable anti-arrhythmic effects.

Clinically, Metoprolol Tartrate covers almost all common cardiovascular diseases with outstanding therapeutic value. For hypertension, it can be used alone or combined with diuretics, calcium channel blockers and ACEI/ARB drugs, suitable for all grades of primary hypertension, especially for patients with tachycardia and coronary heart disease. In the treatment of coronary heart disease and angina pectoris, it balances myocardial oxygen supply and consumption, reduces angina attacks and improves patient exercise tolerance. It is widely used to correct supraventricular and ventricular arrhythmias and stabilize heart rhythm. In addition, it is a core drug for standardized treatment of chronic heart failure. Long-term application reverses ventricular hypertrophy, inhibits myocardial fibrosis, improves cardiac function, and significantly reduces readmission and mortality rates of heart failure patients.

In terms of safety and industrial application, Metoprolol Tartrate has excellent tolerance with a wide therapeutic window. Adverse reactions under conventional doses are mild without obvious liver or kidney toxicity, making it suitable for long-term medication in elderly chronic disease patients. Its high receptor selectivity ensures high safety without causing asthma or cold extremities. At present, the mature industrial production process guarantees stable batch quality and international pharmaceutical grade standards, supporting large-scale production and export supply. With the comprehensive advantages of precise targeting, comprehensive efficacy, high safety and wide adaptability, Metoprolol Tartrate remains an indispensable core API in the global cardiovascular pharmaceutical market, maintaining stable market demand and broad industry development prospects.